Recombinant Factor VIII (Kogenate FS, BAY14-2222)

BIOLOGICAL13 trials

Sponsors

Bayer

Conditions

Blood Coagulation DisordersHaemophilia AHemophilia A

Phase 1

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

CompletedNCT00629837

BayerHemophilia A

Start: 2005-09-30End: 2006-03-31Updated: 2014-11-18

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

CompletedNCT01653639

BayerHemophilia A

Start: 2012-07-31End: 2012-12-31Updated: 2014-01-10

Phase 3

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

CompletedNCT00623480

BayerHemophilia A

Start: 2008-03-31End: 2013-11-30Updated: 2014-11-17

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

CompletedNCT01029340

BayerBlood Coagulation Disorders, Hemophilia A

Start: 2009-12-31End: 2013-03-31Updated: 2016-11-28

Phase 4

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

CompletedNCT01810666

BayerHemophilia A

Start: 2013-03-31End: 2014-01-31Updated: 2015-05-19

Unknown Phase

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

CompletedNCT00874926

BayerHemophilia A

Start: 2008-06-30End: 2013-04-30Updated: 2014-01-29

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

CompletedNCT00922597

BayerHemophilia A

Start: 2008-08-31End: 2011-09-30Updated: 2015-04-20

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan

CompletedNCT00932555

BayerHemophilia A

Start: 2009-04-30End: 2011-12-31Updated: 2012-03-14

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

CompletedNCT00969319

BayerBlood Coagulation Disorders, Hemophilia A

Start: 2009-09-30End: 2014-02-28Updated: 2015-01-19

Prophylaxis Versus On-demand Therapy Through Economic Report

CompletedNCT01159587

BayerHemophilia A

Start: 2004-07-31End: 2010-12-31Updated: 2011-04-13

Kogenate FS Regulatory Post-Marketing Surveillance

CompletedNCT01386268

BayerHemophilia A

Start: 2011-06-30End: 2013-08-31Updated: 2014-08-21

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients

CompletedNCT01436825

BayerHaemophilia A

Start: 2011-10-31End: 2015-07-31Updated: 2015-08-10

Extension at 10 Years of the: Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.

CompletedNCT02581969

BayerHemophilia A

Start: 2016-04-14End: 2018-06-21Updated: 2020-11-18

Related Papers

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials.

2023-06-07

Improvement of Efficacy Outcomes in Patients Who Switched from Sucrose-Formulated rFVIII to BAY 81-8973 Prophylaxis in the LEOPOLD Clinical Trials

Blood2020-11-04

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Blood2019-11-131 citations

Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.

2016-06-2439 citations

Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study

Thrombosis and Haemostasis2015-01-01113 citations